LWCFA
FOLD

Loring Wolcott & Coolidge Fiduciary Advisors’s Amicus Therapeutics FOLD Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-446
Closed -$10K – 453
2020
Q4 		$10K Buy
+446
New +$9.12K ﹤0.01% 566

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's FOLD Position: Q1 2021 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 446 shares — an estimated $10K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in FOLD in Q4 2020 and held it in 1 quarter. The position peaked at $10K in Q4 2020. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 446 Amicus Therapeutics shares in Q1 2021, an estimated $10K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Amicus Therapeutics in Q4 2020 and held it in 1 quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Amicus Therapeutics position peaked at $10K in Q4 2020.
  • 259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q1 2021, filed 14 Apr 2021.